文献速递医院感染防控

对瓣膜提取DNA进行16S rRNA PCR/Sanger测序分子分析及分子药敏试验可改善感染性心内膜炎的诊断与靶向治疗:一项前瞻性研究

Molecular Analysis With 16S rRNA PCR/Sanger Sequencing and Molecular Antibiogram Performed on DNA Extracted From Valve Improve Diagnosis and Targeted Therapy of Infective Endocarditis: A Prospective Study.
PubMed 文献 · Clin Infect Dis · 2023-01-01

该前瞻性队列观察研究纳入2012年4月至2021年5月在本院接受瓣膜手术的连续成年患者,评估分子分析、血培养和瓣膜培养对感染性心内膜炎的诊断及治疗影响,并将分子药敏结果与培养药敏对比。结果显示分子分析在感染性心内膜炎病因诊断中具有高特异性和敏感性,分子药敏可克服分子分析缺乏药敏信息的局限。

要点

  • 在感染性心内膜炎病例中,血培养、瓣膜培养和分子分析的阳性率分别为55%、22%和88%。
  • 62例血培养阴性感染性心内膜炎中57例通过分子分析获得诊断,92%因此改变抗菌治疗。
  • 17份瓣膜标本的分子药敏与培养药敏显示100%一致。

核心结论

  • 分子分析在感染性心内膜炎的病因诊断中显示出高特异性和敏感性。
  • 分子药敏可克服分子分析缺乏药敏试验这一主要局限。
  • 作者主张将分子分析纳入感染性心内膜炎的诊断标准,并在培养结果阴性且分子分析为唯一阳性检测时更广泛地使用分子药敏。

研究设计与样本

  • 前瞻性队列观察研究,纳入2012年4月至2021年5月在本院接受瓣膜手术的连续成年患者。
  • 共纳入137例确诊感染性心内膜炎患者和52例无感染性心内膜炎患者。
  • 评估分子分析、血培养和瓣膜培养的表现,以及分子分析的诊断和治疗影响。
  • 将分子药敏结果与基于培养的抗菌药物敏感性试验进行对比。

主要发现

  • 在感染性心内膜炎病例中,血培养阳性75例(55%),瓣膜培养阳性30例(22%),分子分析阳性120例(88%)。
  • 62例血培养阴性感染性心内膜炎中,57例通过分子分析获得诊断。
  • 分子分析使92%的血培养阴性感染性心内膜炎病例改变了抗菌治疗。
  • 无感染性心内膜炎患者中分子分析100%为阴性。
  • 对17份检出可能携带多重耐药机制编码基因病原体的瓣膜标本进行分子药敏,与抗菌药物敏感性试验显示100%一致。

临床怎么用

  • 作者主张将分子分析纳入感染性心内膜炎的诊断标准。
  • 作者主张当培养结果阴性且分子分析为唯一阳性检测时,更广泛地使用分子药敏。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Molecular analysis (MA) on heart valve (HV) improves the microbiologic diagnosis of infectious endocarditis (IE). The main drawback of MA is the lack of antimicrobial susceptibility information. METHODS: We conducted a prospective cohort observational study of consecutive adult patients from April 2012 to May 2021 who underwent valve surgery at our hospital. The performance of MA, blood cultures (BC) and valve cultures (VC), and the diagnostic and therapeutic impact of MA were evaluated. Molecular antibiogram results were compared to culture-based antimicrobial susceptibility testing (AST). RESULTS: A total of 137 patients with definite IE and 52 patients with no IE were enrolled in the study. Among IE cases BC, VC, and MA were positive in 75 (55%), 30 (22%), and 120 (88%) of IE cases, respectively. Among 62 cases of BC-negative IE (BCNE), 57 achieved diagnosis with MA. MA led to a change of antimicrobial therapy in 92% of BCNE. MA was negative in 100% of patients with no IE. Molecular antibiogram performed on 17 valve specimens that resulted positive for pathogens potential carrier of genes encoding for multidrug resistant mechanisms showed 100% concordance with AST. CONCLUSIONS: MA showed a high specificity and sensitivity in etiological diagnosis of IE. Molecular antibiogram could overcome the major limitation of MA that is the lack of susceptibility testing. We advocate for the inclusion of MA among diagnostic criteria for IE and for a more extensive use of molecular antibiogram when the culture result is negative, and MA is the only positive test.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Mularoni A, Mikulska M, Barbera F, et al. Molecular Analysis With 16S rRNA PCR/Sanger Sequencing and Molecular Antibiogram Performed on DNA Extracted From Valve Improve Diagnosis and Targeted Therapy of Infective Endocarditis: A Prospective Study. Clin Infect Dis. 2023. PMID: 35686318. doi:10.1093/cid/ciac452

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。